SavePeptides
SavePeptidesCompound
Re-checked hourly
All peptides
RecoveryPhase IIIVendors pending
Phase IIIVendors pendingFacts verified · 2026-05-25

Cibinetide

Also known as ARA-290, cibinetide, phbsp, helix b surface peptide · Wikipedia

ARA-290 (cibinetide, pHBSP, helix B surface peptide) is an 11-amino-acid linear peptide engineered from the helix-B region of human erythropoietin (EPO). It is non-erythropoietic - it does not raise hematocrit - because it does not bind the classical EPO receptor homodimer; instead it selectively activates the 'innate repair receptor' (IRR), a heteromer of EPO-R and the beta-common receptor (CD131) expressed on injured tissues and immune cells. Developed by Araim Pharmaceuticals with FDA orphan-drug designation for sarcoidosis-associated small fiber neuropathy and studied in diabetic neuropathy and macular edema. Phase 2 trials have been promising but no Phase 3 program is yet completed.

—

best

price

—

per

mg

—

vendors

tracked

Phase III

stage

Vendor data

Coming soon.

Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.

Browse all vendors

Mechanism of action

Cibinetide (ARA-290) is an 11-amino-acid peptide engineered from the externally exposed helix-B region of erythropoietin. It does not bind the classical (EPO-R)2 homodimer and therefore does not stimulate erythropoiesis.

Cibinetide (ARA-290) is an 11-amino-acid peptide engineered from the externally exposed helix-B region of erythropoietin. It does not bind the classical (EPO-R)2 homodimer and therefore does not stimulate erythropoiesis. Instead it selectively activates the innate repair receptor (IRR), a heteromeric complex of EPO-R with the beta-common receptor (CD131) that is expressed only on injured, stressed, or inflamed tissues (https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/). IRR engagement drives anti-apoptotic, anti-inflammatory, and pro-resolution signaling through JAK2/STAT5, PI3K/Akt, and downstream regulation of cytokine release and macrophage polarization. In clinical work this translates to improvement in corneal nerve fiber density, neuropathic pain, and metabolic control in sarcoidosis-associated small fiber neuropathy (https://pubmed.ncbi.nlm.nih.gov/23168581/, https://pubmed.ncbi.nlm.nih.gov/28475703/) and type 2 diabetes.

Pharmacokinetic properties

Half-life

approximately 2 minutes plasma half-life - but downstream biological effects persist for hours to days due to receptor signaling cascades

Routes

subcutaneous · intravenous

Bioavailability

Despite very short plasma half-life, single daily SC dosing produces sustained pharmacodynamic effects. Not orally bioavailable.

Amino-acid sequence

pyroGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH

Use & research dosing

Anti-InflammatoryNeuropathic SupportRecovery

In Araim Pharmaceuticals trials the most-studied regimen has been 4 mg subcutaneously daily for 28 days, with dose-ranging at 1, 4, and 8 mg/day in the sarcoidosis SFN program. Phase 2a sarcoidosis work used 2 mg IV three times weekly for 4 weeks. Research-use protocols outside trials commonly report 1-4 mg subcutaneous daily in 4-12 week cycles. Not FDA-approved; orphan drug designation only. Research framing.

Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.

Editorial perspective

Among the more clinically validated investigational peptides on this list, with multiple peer-reviewed phase 2 RCTs in sarcoidosis-associated small fiber neuropathy (Heij et al., Dahan group at Leiden) showing improvement in patient-reported neuropathic symptoms and objective corneal-nerve-fiber-density endpoints. Safety in trials has been favorable with no erythropoietic or thrombotic signal. Still investigational in the US; an approved indication and Phase 3 read-out are not yet on the public record.

— SavePeptides editorial desk · last updated 2026-05-25

Cautions & contraindications

Before researching this compound, note:

  • Not FDA-approved; orphan drug designation only for sarcoidosis-associated small fiber neuropathy
  • Clinical-trial safety has been good with no erythropoietic or thrombotic signal at studied doses
  • Long-term safety beyond approximately 6 months of dosing is uncharacterized
  • Theoretical caution with concurrent EPO-class drugs (epoetin, darbepoetin)
  • Pregnancy and lactation - insufficient data; avoid
  • Cost is high relative to other research peptides; identity of grey-market supply uncertain
  • Patients with active malignancy should weigh tissue-protective signaling effects with their oncology team
  • Injection-site reactions reported but typically mild

Research foundation

The papers behind the page.

  1. [01]https://pubmed.ncbi.nlm.nih.gov/23168581/
  2. [02]https://pubmed.ncbi.nlm.nih.gov/28475703/
  3. [03]https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/

Facts verified

2026-05-25

Confidence

medium

What this means

  • No editorial caveats on this entry — claims map to peer-reviewed sources cited above.

How we check →

Vendor data coming soon

All vendors

001 — Independent

We don't list what we wouldn't research.

SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.

002 — Vendor-funded

Free to browse. Supported by referrals.

SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.

003 — Research use

Research-use disclaimer.

SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.